How two bills on the Purple and Orange Books could help drugmakers and doctors
Start adding items to your reading lists:
Create your account
Save this item to:
This item has been saved to your reading list.
Senior Manager, Health Research Institute, PwC USMay 17, 2019
Share this on social media
Developers of generic drugs and biosimilar products may soon find it easier to identify barriers to bringing their products to market through two pieces of legislation unanimously passed by the US House of Representatives last week involving the Orange Book and the Purple Book.
The bills require drug companies to include all patent information applicable to the drug substance, including formulation and methods of use, as well as marketing exclusivity information that would preclude the marketing of a drug. Companies also would be required to notify the FDA if their patent is found to be invalid so it can be removed from the FDA’s database, and the Purple Book would have to be upgraded from its current form—a PDF printout—to a searchable database format.
These valuable databases are used extensively by physicians seeking information about pharmaceuticals, such as the extent to which one drug is generic to another. They are also used by drug manufacturers looking for, for example, patent information.
HRI impact analysis
Increasing the availability and ease with which the public and industry can find and access drug information may benefit developers of generic drugs and biosimilars, as well as physicians. Currently, the Orange and Purple Books lack complete and accurate patent information that would be helpful for developers of generic and biosimilar drugs.
The Purple Book, in particular, lacks all but the most basic information about biological products, leaving developers without any insight into key barriers to market entry and physicians without access to information that would help guide prescribing decisions. For aspiring developers of generics and biosimilars, up-to-date patent information will better help them identify which drugs are subject to competition and the patents they will either need to wait out or challenge.